Farlong Pharmaceutical

Walnut, CA 91789

United States

www.farlong.com

For more than 20 years, Farlong, an herbal ingredient and supplement company, has created products using natural and herbal ingredients to promote a healthy and natural life producing clinically studied, science-backed functional ingredients and products. The company recently received GRAS self-affirmed status for Lifeflower® Breviscapine and Ginseng Plus® Panax Notoginseng™ extract. Farlong has a B2C dietary supplement line, a B2B condition specific functional natural product line for health care professionals and a B2B functional ingredients line for health industry brand owners/formulators/manufactures, along with 8 herb dispensing centers across the U.S. to help practitioners fulfill herb prescriptions.

Expand All

Trademarks

Farlong
Lifeflower
Yunnan NotoGinseng
NotoGinseng
Ginseng Plus

Trademarks

Brands

B2C dietary supplement line, B2B condition specific functional natural product line and a B2B functional ingredients line; also 8 herb dispensing centers across the U.S. to help practitioners.

Associations

American Botanical Council (ABC)

Patents

Panax notoginsenoside composition

A panax notoginsenoside composition for patients having coronary heart disease, high blood pressure, high blood fat, and high cholesterol, consists of 41% by weight of panax notoginsenoside powder extracted from panax notoginseng (Burk.) F. H. chen ex C. Chow et al, 0.5% by weight of beeswax, 58.48% by weight of peanut oil, and 0.02% by weight of BHT.

Patent Number: 6500468 | Patent Date: 12/31/2002

Breviscapinum and extracting process thereof from erigeron breviscapus

An extracting process for extracting breviscapinum from erigeron breviscapus, wherein the breviscapinum has a chemical structure of 4',5,6-trishydroxyflavone-7-glucuronide that can increases cerebral blood flow for significantly decreasing cerebrovascular resistance; raises permeability of blood-brain barrier, increases nutritional blood flow of myocardium; raises immune function of body macrophage cell and counteraction against blood and oxygen depletion induced by hypophyseal pitutrin and thrombocyte agglutination induced by adenosine diphespate inhibiting internal thrombosis and promoting activity of cellulose dissolution; and increases peripheral and coronary bleed flow, effective for sequelas induced by cerebrovascular accident: palsy, coronary heart disease and angina pectoris.

Patent Number: 6084080 | Patent Date: 07/04/2000